Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Cancer Res Clin Oncol. 2011 Jan;137(1):173-81. doi: 10.1007/s00432-010-0871-2. Epub 2010 Apr 8.

Combined analysis of HPV DNA, p16, p21 and p53 to predict prognosis in patients with stage IV hypopharyngeal carcinoma.

Author information

  • 1Laboratory of Anatomy, Faculty of Medicine and Pharmacy, University of Mons, Pentagone 2A-Avenue du Champ de Mars, 6, B-7000 Mons, Belgium.

Abstract

PURPOSE:

We examined p16, p21 and p53 expression in combination with the presence of human papillomavirus (HPV) DNA as molecular markers to predict survival in patients with stage IV hypopharyngeal squamous cell carcinoma (HSCC).

METHODS:

Paraffin-embedded tumours from HSCC patients (n = 75) were evaluated for p16, p21 and p53 expression by immunohistochemistry. HPV DNA was detected by GP5+/6+ consensus PCR and subsequent genotyping by E6/E7 type-specific PCR for HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66 and 68.

RESULTS:

Among the 61 specimens that tested positive for the β-globin, HPV typing identified 50 patients with high-risk (hr) HPV types. HPV 16E7 DNA was detected in 74% (37 cases) of these specimens. Twelve patients were found to be infected with multiple HPV types. However, the presence of hrHPV DNA was not found to correlate with the proportion of disease-free patients. The 5-year disease-free survival rate was 73% in p53- tumours versus 48% in p53+ tumours (P = 0.008).

CONCLUSION:

In our series of patients with stage IV HSCC, the hrHPV+ subgroup had a similar prognosis (in terms of recurrence risk) as the HPV- subgroup. p53 overexpression was associated with a worse prognosis.

PMID:
20376678
[PubMed - indexed for MEDLINE]
PMCID:
PMC3015171
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk